





























Effects of SIRT1 and its activation by resveratrol 
 
SIRT1 is a member of the Sirtuins, a conserved family 
of NAD
+-dependent proteins found to be involved in 
aging processes. Over-expression of the yeast Sir2 
increases lifespan in many organisms, whereas deletion 
or mutations of Sir2 lead to reduced lifespan [1-3]. 
Seven human homologs of Sir2 have been identified, 
named SIRT1 to SIRT7 [4, 5], which can function as 
deacetylase or as mono-ADP-ribosyltransferase. As 
sirtuins are dependent on the NAD
+/NADH ratio, they 
are sensitive to the cellular energy and redox state of the 
cell, conferring them a role as metabolic sensors. SIRT1 
is mainly found in the nucleus, where it functions as a 
transcriptional repressor via histone deacetylation. 
Resveratrol, a natural polyphenol found for instance in 
red grapes and wine, is well recognized as a SIRT1 
activator [6]. Accordingly, resveratrol is the subject of 
great interest since it was shown to exert beneficial 
effects on glucose and lipid metabolism, to improve 
exercise performance, and to extend lifespan in rodents 
[7, 8]. However, detailed mechanisms mediating 
resveratrol effects  remain  unclear  since  this  molecule  
 
 





























has various molecular targets; e.g. SIRT1, AMP-
activated protein kinase (AMPK), or antioxidants 
properties. These targets might be activated differently 
regarding specific organs, rendering extrapolation of the 
mechanisms delineated in one tissue to the other 
hazardous. Therefore, the positive effects of resveratrol 
on glucose homeostasis reported in animal models 
deserves further investigations in order to understand 
the specific contribution of the different organs 
implicated in this response [7, 9, 10]. For instance, 
resveratrol effects might be explained by its action on 
the liver, but also contributed by effects on the 
pancreatic ß-cell. We will now discuss these two tissues 
in more details. 
 
SIRT1 and resveratrol in pancreatic ß-cells 
 
In pancreatic islets, functions and targets of SIRT1 are 
still poorly characterized, as very few studies have 
focused on ß-cells to date. Metabolic efficiency is 
crucial for ß-cell function as glucose metabolism is 
tightly coupled to the control of insulin secretion [11]. 
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in pancreatic ß-cells [12, 13]. The SIRT1 activator 
resveratrol potentiates glucose-stimulated insulin 
secretion, both acutely and secondary to chronic 
treatment. Acutely, resveratrol effects are observed 
already at 1µM in INS-1E insulinoma cells (Figure 1A). 
Following a 24-hour exposure, the effects of resveratrol 
are maintained even after removal of the compound, as 
observed in INS-1E cells and human islets [14]. In islets 
obtained from a type 2 diabetic donor, resveratrol was 
reported to partially restore the secretory response to 
glucose [14]. Several alternative mechanisms may 
explain the chronic effects of resveratrol on insulin 
secreting cells. 
 
Resveratrol can bind to the sulfonylurea receptors 
(SUR), the regulatory subunits of KATP-channels [15]. 







































2+, secondary to the opening of voltage-gated 
Ca
2+ channels, thereby inducing insulin exocytosis. 
Resveratrol is structurally similar to DIDS (4,4’-
dithiocyanatostilbene-2,2’-disulphonic acid), a synthetic 
KATP-channel activator. Moreover, resveratrol treatment 
has been shown to displace binding of the sulfonylurea 
glibenclamide from SUR channels [15]. Therefore, one 
might speculate that resveratrol effects would be similar 
to those of sulfonylureas. In order to test this option, we 
exposed INS-1E cells for 24 hours to sulfonylureas 
(glibenclamide and tolbutamide), DIDS, and 
resveratrol. Glucose-stimulated insulin secretion was 
then tested in the absence of the compounds following 
the 24-hour treatment. As shown in Figure1B, only 
resveratrol potentiated the secretory response, in 
accordance with previous data [14], showing that the 















































































The effects of resveratrol on glucose-stimulated 
insulin secretion are associated with enhanced 
catabolic efficiency of the sugar. Indeed, chronic 
treatment of insulin-secreting cells with resveratrol 
results in elevated glycolytic flux, increased glucose 
oxidation and oxygen consumption, thereby producing 
more ATP upon glucose stimulation [14]. The 
increased metabolism-secretion coupling observed in 
resveratrol-treated cells is favoured by up-regulation 
of the glucose transporter Glut2 and the glycolysis-
initiating enzyme glucokinase, permitting increased 
provision of substrates into the mitochondria. Elevated 
expression of Glut2 and glucokinase might be 
secondary to the reported up-regulation of Pdx1 and 
HNF-1α [14], as these transcription factors regulate 
Glut2 expression [16, 17]. Upstream of these 
regulations, we could show that the effects of 
resveratrol on ß-cells are fully mediated by SIRT1. 
Inhibition of SIRT1, either pharmacologically using 
the EX-527inhibitor or genetically through expression 
of a mutant form lacking deacetylase activity, reduces 
resveratrol effects on glucose-stimulated insulin 
secretion. Conversely, overexpression of SIRT1 in 
INS-1E cells further increases resveratrol effects on 































Collectively, data indicate a sequence of events in 
which resveratrol primarily activates SIRT1, inducing  
expression of key transcription factors for the ß-cell, 
such as Pdx-1 and HNF-1α (Figure 2). This in turn 
promotes expression of Glut2 and glucokinase, thereby 
increasing the secretory response to glucose [14]. 
Hence, resveratrol treatment might mimic starving 
conditions, rendering the ß-cell more sensitive for the 
awaited next rise in glucose levels.  
 
Activation of AMPK by resveratrol and relationship 
to SIRT1 
 
Resveratrol stimulates AMPK in HepG2 hepatoma [18] 
and INS-1E insulinoma [14] cell lines, as well as in 
various tissues [19-21]. Such AMPK pathway could 
account for some of the beneficial effects of resveratrol 
reported in mice fed a high-fat diet [7, 8]. Cross talk 
between AMPK and SIRT1 has been reported in 
different experimental systems [22, 23]. However, 
current information about the hierarchy governing the 
relationship between these two enzymes is at first sight 
contradictory, although discrepancies might reflect 
tissue specificities. Indeed, it was proposed that AMPK 
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 cytes [19], upstream in muscle cells [23, 24], and 
independent of SIRT1 in neurons [20]. In insulin 
secreting cells, we observed that resveratrol treatment 
increased AMPK phosphorylation [14]. However, 
although resveratrol activates both SIRT1 and AMPK, 
only SIRT1 activation accounts for the potentiating 
effects of resveratrol on metabolism-secretion coupling. 
 
SIRT1 and resveratrol in hepatocytes 
 
In the liver, SIRT1 is up-regulated after fasting or 
calorie restriction in rodents [25]. SIRT1 is also 
activated by resveratrol, inducing deacetylation of PGC-
1α and thereby mitochondria biogenesis [7]. Overall, 
activation of hepatic SIRT1 increases gluconeogenic 
genes and represses glycolysis [26].  The gluconeogenic 
activity of hepatocyte nuclear factor 4α (HNF-4α) is 
increased by SIRT1-induced deacetylation of PGC-1α 
[26]. FoxO1, a member of the forkhead transcription 
factors, is also deacetylated by resveratrol, thereby 
promoting hepatic gluconeogenesis [27, 28]. In 
hepatocytes, activation of gluconeogenic gene 
expression by PGC-1α requires close cooperation with 
FoxO1 [29] and HNF-4α [30], regarding for instance 
glucose-6-phosphatase (Figure 2). In rats, administra-
tion of resveratrol results in FoxO1 deacetylation, 
accompanied by repression of glucokinase gene 
expression [27]. In isolated hepatocytes, it was shown 
that the repression of glucokinase induced by 
resveratrol is contributed by the interaction between 
FoxO1 and HNF-4α [27]. Taken as a whole, activation 
of SIRT1 by resveratrol in hepatocytes mimics starving 
conditions, reducing glucose usage and inducing 
glucose production (Figure 2). 
 
SIRT1 mediates different effects in liver and 
pancreatic ß-cell  
 
In most cells types, FoxO1 transcriptional activity is 
switched off by phosphorylation-mediated nuclear 
exclusion. However, when cells are subjected to stress, 
FoxO1 relocates to the nucleus where it is deacetylated 
by SIRT1 [31]. In ß-cells, FoxO1 is constitutively 
phosphorylated, and therefore cytoplasmic, presumably 
reflecting activation of insulin receptor signalling by 
endogenously produced insulin [32]. Induction of 
lipotoxicity by palmitate triggers accumulation of 
FoxO1 into the nucleus of insulin-secreting cells [33] and 
FoxO1 up-regulation impairs insulin secretion in ß-cells 
[34]. Therefore, under normal non-pathological 
conditions, FoxO1 is essentially cytoplasmic in ß-cells, 
regardless of glucose stimulation. Resveratrol treatment 
does not alter the cytoplasmic localization of FoxO1 in 
insulin-secreting cells [14]. In the liver, FoxO1 is 
phosphorylated upon insulin signalling, promoting 
nuclear exclusion [35]. Conversely, low-insulin fasting 
periods favour nuclear localization of FoxO1 in 
hepatocytes and induction of transcriptional activity 
through SIRT1-mediated deacetylation. 
 
PGC-1α is another major target of SIRT1. In 
hepatocytes, PGC-1α induces gluconeogenic machinery 
and represses glucose consumption. In ß-cells, PGC-1α 
over-expression reduces glucose metabolism and the 
accompanying secretory response, suggesting a switch 
to lipid utilization [36]. In diabetic animal models, 
PGC-1α is up-regulated in islets [36] and in the liver 
[37], resulting in increased hepatic glucose production. 
Regarding hepatocyte nuclear factors, treatment of 
insulin secreting cells with resveratrol induces HNF-1α 
gene expression, while HNF-4α is not affected [14].  
 
Overall, SIRT1 activation promotes up-regulation of 
glucokinase in ß-cells, while the same enzyme is down-
regulated in hepatocytes. The apparent contradiction of 
such opposite effects indicates that the common master 
regulator SIRT1 signals starving state to different 




The beneficial effects of resveratrol on the liver and 
pancreatic islets are dependent on SIRT1 activation, 
although SIRT1 targets are different according to each 
tissue (Figure 2). In the liver, resveratrol mostly acts on 
PGC-1α, FoxO1, HNF-4α, and AMPK. In the ß-cell the 
main identified targets are HNF-1α and Pdx1. To date, 
the precise mechanisms of SIRT1 activation are still 
poorly understood, in particular regarding pancreatic 
islets. Tissue specificity renders investigations more 
challenging but at the same time rather fascinating 
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